Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Zhou, W., Ercan, D., Chen, L., Yun, C.H., Li, D., Capelletti, M., Cortot, A.B., Chirieac, L., Iacob, R.E., Padera, R., Engen, J.R., Wong, K.K., Eck, M.J., Gray, N.S., Janne, P.A.(2009) Nature 462: 1070-1074
- PubMed: 20033049 
- DOI: 10.1038/nature08622
- PubMed Abstract: 
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targe ...